Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ophthotech Corp (NASDAQ: OPHT) and NuVasive (NASDAQ: NUVA)

By Austin Angelo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ophthotech Corp (NASDAQ: OPHT) and NuVasive (NASDAQ: NUVA).

Ophthotech Corp (NASDAQ: OPHT)

Stifel Nicolaus analyst Stephen Willey reiterated a Hold rating on Ophthotech Corp (NASDAQ: OPHT) on September 19 and set a price target of $4. The company’s shares closed yesterday at $2.79, close to its 52-week low of $2.24.

According to TipRanks.com, Willey is a 5-star analyst with an average return of 22.9% and a 55.8% success rate. Willey covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Applied Genetic Technologies, and Hutchison China MediTech Ltd.

Ophthotech Corp has an analyst consensus of Hold, with a price target consensus of $3.50.

NuVasive (NASDAQ: NUVA)

Gabelli analyst Jennie Tsai maintained a Buy rating on NuVasive (NASDAQ: NUVA) today. The company’s shares closed yesterday at $53.67, close to its 52-week low of $52.85.

According to TipRanks.com, Tsai is a 4-star analyst with an average return of 18.2% and a 77.4% success rate. Tsai covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, K2M Group Holdings, and Globus Medical.

Currently, the analyst consensus on NuVasive is Strong Buy and the average price target is $80.82, representing a 50.6% upside.

In a report issued on September 7, Piper Jaffray also maintained a Buy rating on the stock with a $90 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.